2018
DOI: 10.12688/f1000research.15796.1
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure. Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 to 9 months in untreated patients. The main therapeutic strategies for MPM are surgery, chemotherapy, and radiation therapy (RT). The two main surgical approaches for MPM are extrapleural pneumonectomy (EPP), in which the lung is remo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
18
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(18 citation statements)
references
References 50 publications
0
18
0
Order By: Relevance
“…Conventional first line treatment for MM consists of chemotherapy (cisplatin and pemetrexed) and more recently also immunotherapy. Chemotherapy is now frequently accompanied by radiotherapy and/or surgery (for review, see [35]) indicating that multimodality treatment appears as the most promising MM treatment strategy. Patient survival is extended on average by only about 1 year by the various treatments and significant improvements in increasing patient survival require the development of new treatment strategies and identification of novel molecules with an appropriate and efficient pharmacological profile, even if recent multimodality trials in early-stage pleural MM show promising results [6].…”
Section: Introductionmentioning
confidence: 99%
“…Conventional first line treatment for MM consists of chemotherapy (cisplatin and pemetrexed) and more recently also immunotherapy. Chemotherapy is now frequently accompanied by radiotherapy and/or surgery (for review, see [35]) indicating that multimodality treatment appears as the most promising MM treatment strategy. Patient survival is extended on average by only about 1 year by the various treatments and significant improvements in increasing patient survival require the development of new treatment strategies and identification of novel molecules with an appropriate and efficient pharmacological profile, even if recent multimodality trials in early-stage pleural MM show promising results [6].…”
Section: Introductionmentioning
confidence: 99%
“…Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer [1,2], consisting of epithelioid, mixed (biphasic) and sarcomatoid histological subtypes [3]. Despite progress in the understanding of the disease etiology, clinical management of MPM patients remains a significant but unmet challenge [4].…”
Section: Introductionmentioning
confidence: 99%
“…Figure 4B represents plot for volumes of spheroids over 15 days of QA treatment (Multiple Dose). Prior to treatment, spheroid volumes for control spheroids and QA-treated spheroids for a multiple dosing regimen were as follows; Control: 4.7 ± 0.2 mm 3 , 5 µM QA: 4.4 ± 0.2 mm 3 ; and for 10 µM QA: 5.1 ± 0.2 mm 3 . No significant differences were observed between spheroid volumes at the beginning of this study ( Figure 4B).…”
Section: Qa Exhibits Excellent Efficacy In An In-vitro 3d Spheroid Momentioning
confidence: 99%
“…[1,2] MM can be classified based on its type and location in the body. For instance, Malignant Pleural Mesothelioma (MPM) is the cancer that affects the pleural lining of the lungs, peritoneal mesothelioma affects the abdominal linings, whereas pericardial mesothelioma affects the lining of the heart [3][4][5]. MM is classified as a rare disease with about 3000 new cases diagnosed in the United States annually.…”
Section: Introductionmentioning
confidence: 99%